Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in levonorgestrel subcutaneous implant users

被引:11
作者
Archer, David F. [1 ]
Philput, Christine B. [2 ]
Levine, Adam S. [3 ]
Cullins, Vanessa [4 ]
Stovall, Thomas G.
Bacon, Janice [5 ]
Weber, Margaret E. [6 ]
机构
[1] Eastern Virginia Med Sch, Jones Inst Reprod Med, CONRAD Clin Res Ctr, Dept Obstet & Gynecol, Norfolk, VA 23507 USA
[2] RTTP Inc, Winchendon, MA 01475 USA
[3] Tampa Obstet Fertil & Gynecol, Brandon, FL 33511 USA
[4] Planned Parenthood Federat Amer, New York, NY 10001 USA
[5] Univ S Carolina, Sch Med, Dept Obstet & Gynecol, Columbia, SC 29209 USA
[6] Med Affairs Dept Wyeth Pharmaceut, Collegeville, PA 19426 USA
关键词
levonorgestrel implants; endometrium; bleeding; ethinyl estradiol; ibuprofen; postcoital test; prospective; double dummy; randomized clinical trial;
D O I
10.1016/j.contraception.2008.04.003
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: The study was conducted to evaluate ethinyl estradiol (EE) or ibuprofen (113U) compared to placebo (PL) on spotting and bleeding (S/13) and a postcoital test (PCT) in women using the levonorgestrel subcutaneous implant. Women experiencing excessive S/B were enrolled in a multicenter prospective randomized study using EE, IBU or PL. Outcome Measures: Duration of S/B and a PCT were evaluated. Statistical analysis used a general linear model procedure with Duncan's multiple range tests for individual variables. Results: One hundred seven women were evaluated, and there was no difference in the duration of bleeding among the three therapies, while the mean number of spotting days were 1.8 for EE and 2.8 for PL (p=.04). There was no effect of IBU on S/13. No effect on cervical mucus or sperm was found between treatments. Conclusion: There was a decrease in spotting but no effect on bleeding with EE compared to PL. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:106 / 112
页数:7
相关论文
共 28 条
[1]  
Abdel-Aleem H, 2007, COCHRANE DATABASE SY
[2]   Hormonal treatment for bleeding irregularities in Norplant implant users [J].
AlvarezSanchez, F ;
Brache, V ;
Thevenin, F ;
Cochon, L ;
Faundes, A .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (03) :919-922
[3]   A multicenter, randomized study of an extended cycle oral contraceptive [J].
Anderson, FD ;
Hait, H .
CONTRACEPTION, 2003, 68 (02) :89-96
[4]   Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results [J].
Archer, David F. ;
Jensen, Jeffrey T. ;
Johnson, Julia V. ;
Borisute, Hannah ;
Grubb, Gary S. ;
Constantine, Ginger D. .
CONTRACEPTION, 2006, 74 (06) :439-445
[5]   Management of irregular uterine bleeding and spotting associated with Norplant(R) [J].
Archer, DF ;
Philput, CA ;
Weber, ME .
HUMAN REPRODUCTION, 1996, 11 :24-30
[6]   LEAS SHIELD(R) - A PHASE-I POSTCOITAL STUDY OF A NEW CONTRACEPTIVE BARRIER DEVICE [J].
ARCHER, DF ;
MAUCK, CK ;
VINIEGRASIBAL, A ;
ANDERSON, FD .
CONTRACEPTION, 1995, 52 (03) :167-173
[7]   Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®) [J].
Archer, DF ;
Maheux, R ;
DelConte, A ;
O'Brien, FB .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (05) :S39-S44
[8]  
Chavez A, 1999, Eur J Contracept Reprod Health Care, V4, P75, DOI 10.3109/13625189909064008
[9]   TREATMENT WITH NORPLANT SUBDERMAL IMPLANTS INHIBITS SPERM PENETRATION THROUGH CERVICAL-MUCUS INVITRO [J].
CROXATTO, HB ;
DIAZ, S ;
SALVATIERRA, AM ;
MORALES, P ;
EBENSPERGER, C ;
BRANDEIS, A .
CONTRACEPTION, 1987, 36 (02) :193-201
[10]   Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding [J].
d'Arcangues, C ;
Piaggio, G ;
Brache, V ;
Aissa, RB ;
Hazelden, C ;
Massai, R ;
Pinol, A ;
Subakir, SB ;
Su-juan, G .
CONTRACEPTION, 2004, 70 (06) :451-462